Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
QTX-2101 + ATRA in Newly Diagnosed Low-risk APL
NCT07504458Phase 3Recruiting
- Sponsor
- Quetzal Therapeutics
- Start
- Jun 2026
- Primary completion
- Mar 2027
- Countries
- 5
01
Overview
Phase 3, randomised, open-label trial of QTX-2101 in acute promyelocytic leukemia (APL) (2 arms), sponsored by Quetzal Therapeutics. Primary endpoints: Maximum observed plasma concentration of QTX-2101 for ASIII at 8 weeks and Molecular complete remission rate at 24 weeks. Started Jun 2026; status: recruiting.
02
Drugs
QTX-2101
03
Conditions
acute promyelocytic leukemia (APL)
Beyond the preview
Go deeper on NCT07504458.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07504458.